Latest Articles

  • The hospital guy redux
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11) 759-760;

    In the September issue of the Journal, Dr. Thomas Lansdale discussed the pressures that are eroding physician-patient relationships and that can corrupt patient care. I am aware of these forces, but I remain a hospital guy because I can still make a difference.

  • Surgical innovation and ethical dilemmas: A panel discussion
    Isador Lieberman, MD, James Herndon, MD, Joseph Hahn, MD, Joseph J. Fins, MD and Ali Rezai, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S13-S21;
  • Surgical innovation and ethical dilemmas: Precautions and proximity
    Joseph J. Fins, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S7-S12;
  • To The Editor: The ENHANCE trial (July 2008)
    Gil Porat, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11) 763-767;
  • New surgical devices and ethical challenges: A collection of perspectives and panel discussion
    Daniel Schultz, MD, Mary H. Mcgrath, MD, MPH, Thomas H. Murray, PhD, Roy K. Greenberg, MD and Thomas J. Fogarty, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S74-S84;
  • Preface
    Lawrence K. Altman, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S61;
  • The ENHANCE trial (July 2008)
    William H. Fee, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11) 763;

    Does ezetimibe still have a role? Comments on our article in the July 2008 issue describing the surprising results of an important trial.

  • Medical professionalism in a commercialized health care market
    Arnold S. Relman, MD
    Cleveland Clinic Journal of Medicine November 2008, 75 (11 suppl 6) S33-S36;
  • An update on proteinuric chronic kidney disease: The dual-goal approach
    Sheldon Hirsch, MD
    Cleveland Clinic Journal of Medicine October 2008, 75 (10) 705-713;

    To slow the progression of proteinuric chronic kidney disease, we may need to set goals for lowering both blood pressure and urinary albumin excretion, using drugs that block the renin-angiotensin-aldosterone system at multiple sites or in higher doses. However, this dual-goal approach needs to be validated prospectively.

  • Biochemical markers of bone turnover: Useful but underused
    Angelo A. Licata, MD
    Cleveland Clinic Journal of Medicine October 2008, 75 (10) 751-752;

    Markers tell us the risk of fracture and are useful in patient management. But will insurance pay for testing?

Pages